Life Sciences – Weekly Industry News

(BW) Teva and Mylan Settle Copaxone(R) Patent Litigation in France, the UK and the Netherlands, Posted on The Wall Street Journal JERUSALEM–(BUSINESS WIRE)–November 25, 2013–  Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone(R) (glatiramer acetate) in the United…

Life Sciences – Weekly Industry News

Another Roche move against biosimilars: Kadcyla now approved in EU, Posted on Biosilimar News Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. Specifically, Kadcyla is indicated as a…